CCEL reported a slight decline in its second-quarter revenue, bringing in $7.9 million compared to $8.0 million in the same period last year. The financial results reflect a minor revenue contraction on a year-over-year basis. Investors might consider evaluating this performance in the context of broader market conditions and company strategy.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Cryo-Cell International Inc (CCEL, Financial) is $8.50 with a high estimate of $8.50 and a low estimate of $8.50. The average target implies an upside of 73.12% from the current price of $4.91. More detailed estimate data can be found on the Cryo-Cell International Inc (CCEL) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Cryo-Cell International Inc's (CCEL, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cryo-Cell International Inc (CCEL, Financial) in one year is $6.53, suggesting a upside of 33% from the current price of $4.9098. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cryo-Cell International Inc (CCEL) Summary page.
